title: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
authors.affiliation: Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria; Queensland Institute of Medical Research; School of Medicine, University of Queensland, Herston, Queensland, Australia.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
authors.affiliation: Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Yagita
authors.affiliation: Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria grant.mcarthur@petermac.org.
authors.forename: Grant A
authors.initials: GA
authors.lastname: McArthur
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary / Q000601:surgery; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors* / Q000276:immunology; D000069448:Denosumab / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000556:secondary; D049268:Positron-Emission Tomography; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D053245:RANK Ligand / Q000037:antagonists & inhibitors* / Q000276:immunology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D051598:Whole Body Imaging / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf